In 5 years, some dialysis innovations may not fail because they are unsafe, ineffective, or scientifically boring, but because the path to keeping them available became too expensive and tangled. Here's why.

A new PubMed-indexed paper on medical device regulation and dialysis practice raises a surprisingly thorny question: what happens when rules designed to make medical devices safer also make some devices disappear? That is not a tiny paperwork problem. In chronic haemodialysis, where patients depend on machines, filters, bloodlines, needles, catheters, monitors, and highly specialized equipment several times a week, the device ecosystem is not background scenery. It is the plumbing, wiring, and stage crew of survival. If one niche component vanishes, the whole production can start looking like a hospital version of musical chairs, except nobody wanted music and all the chairs are prescription-only.

The MDR: A Safety Upgrade With Side Effects

The European Union's Medical Device Regulation, usually called the MDR, was adopted in 2017 to replace the older Medical Device Directive. On paper, the motivation makes immediate sense. Medical devices should be safe. Manufacturers should have solid clinical evidence. Regulatory bodies should scrutinize products carefully. Devices should be traceable, so if something goes wrong, people can figure out where it came from, who used it, and what needs fixing.

That sounds reasonable. Honestly, it sounds like the sort of system you would want if a machine were cleaning your blood three times a week.

But the paper argues that, in chronic haemodialysis, the MDR has had a substantial and sometimes negative impact. The new requirements have raised the burden on manufacturers, especially for niche devices that serve smaller patient populations. When the market is small, the cost of proving compliance can become large enough that companies simply stop offering a product.

This is where the story gets interesting, and a little uncomfortable. Regulation is often discussed as a simple slider: less regulation means more innovation, more regulation means more safety. Real life, being annoyingly committed to complexity, refuses to behave like a slider. It is more like a mixing board with 47 knobs and one of them is labeled "paediatric dialysis catheter availability."

Why Dialysis Is Especially Vulnerable

Dialysis is not one device. It is a tightly coordinated system.

In haemodialysis, blood is drawn from the body, passed through a dialyser that filters waste products and excess fluid, then returned to the bloodstream. The dialyser acts a bit like an artificial kidney, although kidneys should get credit for being far more elegant and not requiring wall outlets. Patients with kidney failure may rely on this treatment for years, sometimes for life, unless they receive a transplant.

That long-term dependence changes the stakes. A device shortage is not merely an inconvenience. It can alter treatment schedules, limit options for children, force clinicians to improvise within narrow safety margins, or prevent patients from receiving the equipment best suited to their needs.

The paper highlights paediatric nephrology as a particularly hard-hit area. Children are not simply small adults from a device-design perspective. They may need smaller tubing volumes, specialized filters, tailored catheters, or machines that can handle lower blood flow rates. These are often niche products, which means the business case for keeping them on the market may already be thin. Add more regulatory cost, and the math can start making manufacturers quietly back away.

That is a serious problem, because children with kidney failure do not become less medically complex just because a spreadsheet got nervous.

The Innovation Problem

The EuDial board, which discussed these developments, concluded that the MDR has had a clear negative impact on innovation in dialysis devices. That does not mean safety regulation is bad. It means the current system may be creating friction in places where the benefits are not always balanced against the unintended consequences.

Innovation in dialysis is already challenging. Devices must be dependable, biocompatible, cleanable or sterile, compatible with existing clinical workflows, and usable by busy care teams under pressure. A flashy idea is not enough. A dialysis product has to work on Tuesday morning, Friday afternoon, during staff shortages, and when a patient has unusual vascular access needs. It needs to be boring in the best possible way.

But innovation also needs oxygen. If regulatory pathways become too expensive or uncertain, smaller companies may avoid dialysis altogether. Larger companies may focus only on high-volume devices. Incremental improvements, which can matter enormously in real clinical practice, may never reach patients.

This is the quiet kind of innovation loss. There is no dramatic failed gadget launch. No cinematic boardroom collapse. Just fewer options, fewer updates, and fewer people willing to build the specialized tools that clinicians and patients actually need.

Supply Chains Are Not Magical

The abstract also connects MDR pressures with broader economic trends and supply chain risks. This is not surprising, but it is worth pausing on.

Healthcare supply chains can look sturdy until they are not. Dialysis depends on reliable access to disposables, replacement parts, fluids, filters, and machines. If one manufacturer exits a niche category, the remaining suppliers become more important. If those suppliers then face production delays, raw material costs, shipping disruptions, or regulatory bottlenecks, the system has less slack.

In engineering terms, redundancy shrinks. In ordinary human terms, everyone starts sweating.

The COVID-19 pandemic made many people newly aware that medical supplies do not teleport into clinics by moonlight. Dialysis supply chains are especially sensitive because treatments are repeated, scheduled, and resource-intensive. A shortage cannot easily be solved by telling patients to come back in six months. Dialysis is not a dentist appointment.

What Could a Better Balance Look Like?

The paper says the authors offer actionable recommendations to preserve the benefits of the MDR while reducing unintended harm. Based on the issues described, the broad direction seems clear: regulators, clinicians, patient groups, and manufacturers need a more nuanced system for devices that are essential, low-volume, or used in vulnerable groups.

That might include smarter proportionality in evidence requirements, especially for devices with long histories of safe use. It could mean special pathways for paediatric dialysis equipment or other niche products where market incentives are weak but clinical need is strong. Better coordination between regulators and clinical experts could also help identify shortages before they become emergencies.

Traceability and safety oversight still matter. Nobody wants a regulatory free-for-all where the official approval process is a shrug and a clipboard. But a system can be strict and still adaptive. The goal should be to catch unsafe devices without accidentally flattening the ecosystem of useful ones.

Why This Paper Matters

What makes this research intriguing is that it looks at regulation not as an abstract policy debate, but as something that reaches all the way to the dialysis chair. A rule written in legal language can eventually determine whether a child has access to a suitable device, whether a clinician has enough treatment options, and whether a manufacturer decides to keep making a specialized product.

That chain of consequences is easy to miss. Medical progress is not just about brilliant discoveries and dramatic breakthroughs. It also depends on the dull-sounding infrastructure that lets useful tools stay available. Forms, audits, standards, notified bodies, supply contracts: not glamorous, but neither is a kidney filter until you need one.

The uncomfortable lesson is that patient safety has more than one dimension. A device can be unsafe because it is poorly tested. But patients can also be put at risk when safe, needed devices vanish from the market. Good regulation has to see both sides at once.

That is a harder job than simply tightening every rule. It requires judgment, feedback, and the humility to notice when a well-intended system is producing side effects. Regulation, like medicine itself, needs follow-up.

This blog post discusses research findings and should not be taken as medical advice. If you have concerns about kidney disease, dialysis, or medical device availability, please consult a healthcare provider. Research discussed here represents ongoing scientific investigation and clinical validation is still in progress.

All images used in this post are decorative illustrations only and do not represent or reflect the accuracy, reality, or correctness of the referenced research.

Primary Source: Medical device regulation and dialysis practice-impact on patients, doctors and manufacturers. PubMed Record 41459722. https://pubmed.ncbi.nlm.nih.gov/41459722/